Researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, have identified a new biomarker called TTF-1 that can help physicians predict the outcome for patients with a specific type of non-small cell lung cancer (NSCLC). Patients with KRAS G12C- mutated NSCLC and high expression of TTF-1 had better chances of survival upon being treated with the KRAS inhibitor sotorasib, while patients with tumors that express low TTF-1 levels responded poorly to the treatment.

“Since TTF-1 testing is routinely performed in lung cancer diagnosis, it gives physicians an immediate tool to help identify those patients who may benefit from sotorasib and those who may need an alternative or intensified treatment approach,” explained Ferdinandos Skoulidis, MD, PhD, Associate Prof

See Full Page